So great that HER2+ GEA has many promising new tx’s! The next yrs will be important for us to study how to optimally sequence of all of them to best treat our pts!!
#margetuximab #tras #tucatinib #trasderux #zw25 etc...
#retifanlimab #pembro #nivo etc...
thelancet.com/journals/lanon…
#margetuximab #tras #tucatinib #trasderux #zw25 etc...
#retifanlimab #pembro #nivo etc...
thelancet.com/journals/lanon…
In addition to the main text, be sure to check out pages 4-11 of the supplement. Lots of good stuff buried there. Most important to me are the biomarker subgroups analyses: “Targeted therapies for targeted populations!” Some long-term survival noted in the double-positive group.
Important observations to me:
1. All observed responses were IHC 3+ at 1L dx.
2. 79% of responses were PDL1 CPS>1 at 1L dx
3. 88% of responses were ctDNA HER2+ at time of enrollment prior to 2L tx on study.
4. ⬆️est response was amongst those with all 3 of those biomarkers+.
1. All observed responses were IHC 3+ at 1L dx.
2. 79% of responses were PDL1 CPS>1 at 1L dx
3. 88% of responses were ctDNA HER2+ at time of enrollment prior to 2L tx on study.
4. ⬆️est response was amongst those with all 3 of those biomarkers+.
These data generated the hypothesis that a chemo-free dual-AB approach may be effective in these highly biomarker selected pts, which is now being prospectivly tested in the ongoing 1L ‘cohort A’ of the MAHOGANY study! 🤞🏼💪🏼NCT04082364
clinicaltrials.gov/ct2/show/NCT04…
clinicaltrials.gov/ct2/show/NCT04…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
